Ebastine to treat liver cancer with tumor budding after surgery
Part of Cancer clinical trials.
This trial tests if the allergy medicine ebastine can help prevent liver cancer from coming back after surgery. It is for people whose tumor cells show 'budding' (a sign of aggressive growth) and who are otherwise healthy enough for follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that has not spread to other parts of the body
- Your tumor test shows 'tumor budding' is present
- Your doctor expects you to live at least 12 more weeks
- Your liver cancer was successfully removed with surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for people with liver cancer who have a specific tumor feature called 'positive tumor budding' and have already had surgery to remove the cancer. The goal is to find the best treatment to give after surgery to help prevent the cancer from coming back.
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
This trial tests a combination treatment for liver cancer that cannot be surgically removed. It combines a procedure called TACE (which blocks blood flow to the tumor) with targeted drugs and immunotherapy (helping your immune system fight the cancer). The goal is to see if this combined approach works better and is safe.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Hear when a new Hepato Cellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.